Neurotech International Limited announced that after two years of partnership on local tests and submissions to the Taiwan Food & Drug Administration, Neurotech have signed Holy Stone Healthcare as the exclusive distributor in Taiwan. The three-year agreement with Holy Stone Healthcare confirmed exclusive distribution for the territory of Taiwan. The agreement is subject to successful approval from the TFDA which is anticipated to be in the first quarter of 2020.

The agreement is otherwise subject to standard commercial terms for contracts of this nature.